C12N 2310/3531
Hydrogen
C12N2310/3531 (Hydrogen) appears on 110 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 110
- Published applications
- 47
- Assignees
- 24
- Inventors
- 106
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 10 | 0 |
| 1997 | 17 | 0 |
| 1998 | 11 | 0 |
| 1999 | 11 | 0 |
| 2000 | 7 | 0 |
| 2001 | 7 | 3 |
| 2002 | 11 | 3 |
| 2003 | 4 | 9 |
| 2004 | 3 | 5 |
| 2005 | 2 | 3 |
| 2006 | 4 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 0 |
| 2013 | 2 | 2 |
| 2014 | 2 | 3 |
| 2015 | 2 | 2 |
| 2016 | 2 | 3 |
| 2017 | 0 | 0 |
| 2018 | 2 | 1 |
| 2019 | 1 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 2 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Polyribonucleotide containing deuterated nucleotides13 Jan 2026US 12,522,821 B2ethris GmbH
- RNA interference agents for GST-PI gene modulation28 Feb 2023US RE49,431 E1Nitto Denko Corporation
- Methods and compositions for treating malignant tumors associated with KRAS mutation4 Oct 2022US RE49,229 E1Nitto Denko Corporation
- RNA interference compositions and methods for malignant tumors11 Jan 2022US RE48,887 E1Nitto Denko Corporation
- RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (SINA)6 Oct 2020US 10,793,860 B2Sirna Therapeutics, Inc.
- Treatment of amyotrophic lateral sclerosis6 Jun 2024US 2024/0182903 A1Biogen MA Inc.
- Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same6 Jul 2023US 2023/0212582 A1Nogra Pharma Limited
- Polyribonucleotide containing deuterated nucleotides14 Jan 2021US 2021/0009995 A1ethris GmbH
- Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)25 Jun 2020US 2020/0199596 A1Sirna Therapeutics, Inc.
- Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)12 Jul 2018US 2018/0195071 A1Sirna Therapeutics, Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997